Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study to Assess Whether Etrolizumab is a Safe and Efficacious Treatment for Participants With Moderately to Severely Active Crohn's Disease
- First Posted Date
- 2015-03-20
- Last Posted Date
- 2022-11-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1035
- Registration Number
- NCT02394028
- Locations
- 🇺🇸
Innovative Medical Research of South Florida, Aventura, Florida, United States
🇦🇹LKH - Universitätsklinikum der PMU Salzburg, Salzburg, Austria
🇭🇷Clinical Hospital Center Sestre Milosrdnice, Zagreb, Croatia
Human Epidermal Growth Factor Receptor 2 (HER2) Positive Unresectable Locally Advanced or Metastatic Breast Cancer Disease Registry Study
- Conditions
- Breast Cancer
- Interventions
- Other: No intervention
- First Posted Date
- 2015-03-20
- Last Posted Date
- 2024-02-21
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 311
- Registration Number
- NCT02393924
- Locations
- 🇬🇧
Kent & Canterbury Hospital, Canterbury, United Kingdom
🇬🇧Chesterfield Royal Hospital, Chesterfield, United Kingdom
🇬🇧Royal Cornwall Hospital; Dept of Clinical Oncology, Cornwall, United Kingdom
BELOVA Data Collection: Safety and Efficacy of Frontline Bevacizumab Treatment in Participants With Ovarian Cancer 70 Years and Older
- First Posted Date
- 2015-03-20
- Last Posted Date
- 2019-07-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 76
- Registration Number
- NCT02393898
- Locations
- 🇧🇪
UZ Antwerpen, Edegem, Belgium
🇧🇪Sint Augustinus Wilrijk, Wilrijk, Belgium
🇧🇪UZ Leuven Gasthuisberg, Leuven, Belgium
A Study of Treatment With RO6864018 in Virologically Suppressed Participants With Chronic Hepatitis B Virus (HBV) Infection
- Conditions
- Hepatitis B, Chronic
- Interventions
- First Posted Date
- 2015-03-18
- Last Posted Date
- 2018-06-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 31
- Registration Number
- NCT02391805
- Locations
- 🇲🇾
University Malaya Medical Center, Kuala Lumpur, Malaysia
🇰🇷Seoul National University Hospital, Seoul, Korea, Republic of
🇰🇷Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of
Retrospective Data Collection: Post Study Treatment Anticancer Therapy From IMELDA MO22223
- Conditions
- Breast Cancer
- Interventions
- Other: No Intervention
- First Posted Date
- 2015-03-09
- Last Posted Date
- 2018-04-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 185
- Registration Number
- NCT02383576
- Locations
- 🇪🇸
Hospital Virgen de los Lirios; Servicio de Oncologia, Alcoy, Alicante, Spain
🇪🇸Corporacio Sanitaria Parc Tauli; Servicio de Oncologia, Sabadell, Barcelona, Spain
🇧🇷Hospital de Caridade de Ijui; Oncologia, Ijui, RS, Brazil
A Study to Evaluate the Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil (MMF) in Participants With Pemphigus Vulgaris (PV)
- Conditions
- Pemphigus Vulgaris
- Interventions
- First Posted Date
- 2015-03-09
- Last Posted Date
- 2020-11-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 135
- Registration Number
- NCT02383589
- Locations
- 🇹🇷
Gülhane Military Medical Academy in Ankara, Ankara, Turkey
🇪🇸Hospital de la Victoria, Malaga, Spain
🇺🇦Dnipropetrovsk State Medical Academy, Dnipropterovsk, Ukraine
A Study to Assess the Effectiveness and Safety of Vismodegib (Erivedge®) in Participants With Advanced Basal Cell Carcinoma (BCC)
- First Posted Date
- 2015-02-26
- Last Posted Date
- 2020-10-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 50
- Registration Number
- NCT02371967
- Locations
- 🇸🇪
Skånes Universitetssjukhus; Hudkliniken, Lund, Sweden
🇸🇪SU/Sahlgrenska, Hudkliniken, Göteborg, Sweden
🇸🇪Norrlands universitetssjukhus; Onkologkliniken, Umeå, Sweden
A Study of Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Carcinoma, Non-Squamous Non-Small Cell Lung
- Interventions
- First Posted Date
- 2015-02-20
- Last Posted Date
- 2021-08-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 723
- Registration Number
- NCT02367781
- Locations
- 🇺🇸
University of Miami School of Medicine - Sylvester at Deerfield, Deerfield Beach, Florida, United States
🇺🇸Fort Wayne Med Oncology & Hematology Inc, Fort Wayne, Indiana, United States
🇺🇸SCRI Florida Cancer Specialists East, West Palm Beach, Florida, United States
A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131]
- Conditions
- Squamous Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2015-02-20
- Last Posted Date
- 2022-03-21
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1021
- Registration Number
- NCT02367794
- Locations
- 🇺🇸
Southern CA Permanente Med Grp, Bellflower, California, United States
🇺🇸Kaiser Permanente Oakland Medical Center, Oakland, California, United States
🇺🇸Kaiser Permanente - Santa Clara, Santa Clara, California, United States
A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2015-02-19
- Last Posted Date
- 2021-09-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1202
- Registration Number
- NCT02366143
- Locations
- 🇺🇸
Piedmont Cancer Institute, PC, Atlanta, Georgia, United States
🇺🇸Univ of Pittsburgh Medical Ctr, Pittsburgh, Pennsylvania, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States